Keros Therapeutics Posts Q2 2026 Loss of $1.45/Share, Extends Cash Runway into 2028, and Launches Phase 2 DMD Trial

summarizeSummary

Keros Therapeutics recorded a Q2 2026 net loss of $28.7M ($1.45/share) and held $257.6M in cash, extending its runway into 2028. The company also initiated a Phase 2 trial for rinvatercept in DMD, with data anticipated in H1 2027.

check_boxKey Events · Earnings and Guidance · KROS

• Q2 2026 Net Loss Widens

  The net loss reached $28.7M ($1.45 per share), compared with $30.7M ($0.76 per share) in Q2 2025, as Takeda-related revenue disappeared.

• Cash Runway Extended to H1 2028

  Cash and cash equivalents stood at $257.6M as of June 30, 2026, down from $287.4M at year-end 2025, and are projected to fund operations into the first half of 2028.

• Phase 2 DMD Trial Initiated

  A Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy has commenced; initial data are expected in the first half of 2027.

• Operating Expenses Decline Sharply

  R&D expenses dropped to $22.3M from $43.5M in Q2 2025, while G&A fell to $8.6M from $14.5M, reflecting the Takeda transition and the 2025 restructuring.

auto_awesomeAnalysis · KROS · Life Sciences

A Q2 net loss of $28.7 million, or $1.45 per share, widened from the prior quarter's $1.21 loss as revenue evaporated following the Takeda deal. Operating expenses, however, contracted sharply—R&D nearly halved with elritercept costs shifting to Takeda. With $257.6 million in cash, the company now has a runway into the first half of 2028. Adding to the pipeline momentum, a Phase 2 trial for rinvatercept in DMD has begun, and initial data are expected in the first half of 2027. Given that the stock is hovering near its 52-week low, the extended cash runway and clinical progress are vital for restoring investor confidence.